Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
LIMBER-313 trial: what clinicians have said so far
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
- NCT04551066 ↗
- Terminated
- Incyte Corporation
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on LIMBER-313 (parsaclisib plus ruxolitinib in myelofibrosis) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on LIMBER-313 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kδ Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis
- Phase
- Phase 3
- Status
- Terminated
- Conditions
- Myelofibrosis; Primary Myelofibrosis; Post Essential Thrombocythemia Myelofibrosis; Post Polycythemia Vera Myelofibrosis
- Interventions
- parsaclisib; ruxolitinib; placebo
- Arms
- Group A : parsaclisib + ruxolitinib · Experimental
- Group B : placebo + ruxolitinib · Placebo comparator
- Enrollment
- 252
- Primary outcomes
- Percentage of Participants Achieving ≥35% Reduction in Spleen Volume From Baseline to Week 24 as Measured by Magnetic Resonance Imaging [MRI] (or Computed Tomography [CT] Scan in Applicable Participants)
- Sponsor
- Incyte Corporation
- Start
- May 24, 2021
- Primary completion
- Aug 3, 2023
- Results posted
- Yes
- Registry record
- NCT04551066 · updated Oct 21, 2025